Mr. Aselage has more than 30 years of pharmaceutical and biotechnology experience, most recently serving as Chief Executive Officer of Travere Therapeutics (TVTX) (formerly Retrophin, Inc.) from 2014 to 2019. Previously, he was Executive Vice President and Chief Business Officer of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, he built the commercial and medical affairs functions that launched three commercial products and developed commercial businesses in more than 45 countries. Mr. Aselage has also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences and Genentech. He worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat. Earlier in his career, he held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) and Bristol Laboratories. Mr. Aselage received his B.S. in Biology from the University of Notre Dame. In addition, Mr. Aselage currently serves on the Advisory Council for the Department of Science at Notre Dame and also serves on the Board of Directors at BioCryst.
